TGFB1 and melanoma: Several studies have reported that interferon‐γ (IFN‐γ) signaling also drives beneficial clinical responses to ICI in melanoma.[36] We observed the clinical outcomes of ICI‐treated patients with NSCLC for 4.85 years and assert that neither TGF‐β nor IFN‐γ impacts the clinical outcome of patients with NSCLC treated with ICI (Figure 1b).